Aztreonam–avibactam for the treatment of serious infections caused by metallo-β-lactamase-producing Gram-negative pathogens: a Phase 3 randomized trial (ASSEMBLE)
JAC-Antimicrobial Resistance · 02.07.2025 · 7 (4)
DOI: 10.1093/jacamr/dlaf131 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 28.07.2025. Verfasst von George L Daikos und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, National and Kapodistrian University of Athens, 115-27 Athens, Greece. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United States Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority.
Abstract (Originalsprache)
Background
The Phase 3 ASSEMBLE study investigated aztreonam–avibactam versus best available therapy (BAT) for treatment of complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI), hospital-acquired/ventilator-associated pneumonia (HAP/VAP) or bloodstream infection (BSI) caused by confirmed MBL-producing multidrug-resistant pathogens.
Methods
This prospective, multicentre, randomized, open-label, central assessor-blinded study randomized hospitalized adults 2:1 to aztreonam–avibactam [+ metronidazole (cIAI)] or BAT for 5–14 (cIAI, cUTI and BSI) or 7–14 (HAP/VAP) days. Primary endpoint was clinical cure at test-of-cure (TOC) visit on Day 28 ± 3 [microbiological ITT (micro-ITT) analysis set]. Secondary endpoints included microbiological response at TOC, 28-day mortality and safety. No formal hypothesis testing was planned.
Results
Fifteen patients were randomized [aztreonam–avibactam, n = 12; BAT, n = 3 (ITT and micro-ITT analysis sets)]. Most frequent baseline pathogens were Enterobacterales; Klebsiella pneumoniae was most common [aztreonam–avibactam, 6/12 (50%); BAT, 2/3 (67%)]. MBL subtypes/variants identified in the aztreonam–avibactam group were NDM-1 (n = 7), NDM-5 (n = 3), VIM-2 (n = 2) and L1 (n = 3); and for BAT were NDM-1 (n = 2) and NDM-5 (n = 1). Clinical cure rates at TOC were 5/12 (42%) for aztreonam–avibactam and 0/3 (0%) for BAT. Per-patient microbiological responses were generally consistent with clinical responses. Twenty-eight-day all-cause mortality rates for aztreonam–avibactam and BAT were 1/12 (8%) and 1/3 (33%), respectively. Aztreonam–avibactam was generally well-tolerated, with no treatment-related serious adverse events.
Conclusions
These Phase 3 data provide support for aztreonam–avibactam as a potential therapeutic option for difficult-to-treat infections caused by MBL-producing Gram-negative bacteria.
Autor:innen und Institutionen
- Department of Medicine, National and Kapodistrian University of Athens, 115-27 Athens, Greece.
- Virgen del Rocío University Hospital-IBiS, CIBERINFEC, Seville, Spain.
- The National Center for Antibiotic Resistance and Infection Control, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
- Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
- Key Laboratory of Clinical Pharmacology of Antibiotics, National Heath Commission of People's Republic of China, Shanghai, China.
- Department of Medicine, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.
ORCID-Profile: George L Daikos, Minggui Wang, Pinyo Rattanaumpawan, Anca Streinu-Cercel, Rienk Pypstra
Förderung
- United States Department of Health and Human Services
- Administration for Strategic Preparedness and Response
- Biomedical Advanced Research and Development Authority
Zitieren
APA
Daikos, G. L., Cisneros, J. M., Carmeli, Y., Wang, M., Leong, C. L., Pontikis, K., Anderzhanova, A., Florescu, S., Kozlov, R., Rodriguez-Noriega, E., Psichogiou, M., Rattanaumpawan, P., Streinu-Cercel, A., Ramasubramanian, V., Arhin, F. F., Rogers, H., Wible, M., Leaney, J., Jacobson, D., …, & Chow, J. W. (2025). Aztreonam–avibactam for the treatment of serious infections caused by metallo-β-lactamase-producing Gram-negative pathogens: a Phase 3 randomized trial (ASSEMBLE). JAC-Antimicrobial Resistance, 7(4). https://doi.org/10.1093/jacamr/dlaf131
Vancouver
Daikos GL, Cisneros JM, Carmeli Y, Wang M, Leong CL, Pontikis K, et al. Aztreonam–avibactam for the treatment of serious infections caused by metallo-β-lactamase-producing Gram-negative pathogens: a Phase 3 randomized trial (ASSEMBLE). JAC-Antimicrobial Resistance. 2025;7(4). doi:10.1093/jacamr/dlaf131
BibTeX
@article{Daikos2025,
author = {Daikos, George L and Cisneros, José Miguel and Carmeli, Yehuda and Wang, Minggui and Leong, Chee Loon and Pontikis, Konstantinos and Anderzhanova, Anastasia and Florescu, Simin and Kozlov, Roman and Rodriguez-Noriega, Eduardo and Psichogiou, Mina and Rattanaumpawan, Pinyo and Streinu-Cercel, Anca and Ramasubramanian, Venkatasubramanian and Arhin, Francis F and Rogers, Halley and Wible, Michele and Leaney, Joanne and Jacobson, Daria and Pypstra, Rienk and Chow, Joseph W},
title = {Aztreonam–avibactam for the treatment of serious infections caused by metallo-β-lactamase-producing Gram-negative pathogens: a Phase 3 randomized trial (ASSEMBLE)},
journal = {JAC-Antimicrobial Resistance},
year = {2025},
volume = {7},
number = {4},
doi = {10.1093/jacamr/dlaf131}
}
EUVIMED